New scientific data suggest that fear, stress and the physical bulk of AAIs are significant, often underappreciated barriers that may prevent many people at risk of anaphylaxis from consistently ...
Rising electricity demand from AI and data centers is driving plans to expand nuclear power capacity, possibly including on-site small modular reactors (SMRs)¹Medical countermeasures need to scale alo ...
Trade talks between the US and Canada broke down last week, leading to a wave of tariffs and retaliatory tariffs. US President Donald Trump also fell back on an old favorite to needle his opponents, ...
SAN DIEGO, July 07, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect ...
SAN DIEGO, June 24, 2026 (GLOBE NEWSWIRE) -- ARS Pharmaceuticals, Inc. (Nasdaq: SPRY), a biopharmaceutical company dedicated to empowering at-risk patients and their caregivers to better protect ...
ARS Pharmaceuticals is now focused on scaling Neffy. This is their needle-free epinephrine spray for severe allergic reactions, and it’s also core to my bull case on SPRY. Recently, we’ve seen SPRY ...
Northland Highlights ARS Pharmaceuticals, Inc. (SPRY) Needle-Free Therapy as Major Innovation Driver
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
neffy® (epinephrine nasal spray) Approved in Japan as the First and Only Needle-Free Emergency Treatment of Allergic Reactions (anaphylaxis) In 2020, ARS Pharma entered into an exclusive licensing ...
Credit: ARS Pharmaceuticals. Each carton contains 2 blister packages each with a single-dose nasal spray product for 1 time use. It is recommended that patients be prescribed and have immediate access ...
ARS Pharmaceuticals has a recently launched needle-free epinephrine product for allergic reactions, neffy, and strong cash reserves. The company targets a ~$3B+ U.S. market, geographic expansion and ...
Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS Pharmaceuticals received the green light from health regulators for a ...
Parents and pediatricians just gained one more tool to combat severe allergic reactions in young kids. San Diego-based ARS Pharmaceuticals received the green light from health regulators for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results